A red-shifted Renilla luciferase for transient reporter-gene expression
To the Editor: The principal limitation when using Renilla reniformis luciferase (RLuc) as a reporter for bioluminescence imaging in small-animal models has been that, because of its blue-peaked (481-nm) emission spectrum and the preferential absorption of short-wavelength photons by biological tissues, RLuc has diminished sensitivity at non-superficial locations 1 . To overcome this, we previously developed the red-shifted variant RLuc8.6-535 (ref. 2) , which, in addition to having enhanced enzymatic activity compared to the native luciferase, shows an additional threefold increase in sensitivity at non-superficial tissue depths because of its green-peaked (535-nm) emission spectrum. RLuc8.6-535 was derived from the variant RLuc8 (ref. 3 ) and retains RLuc8's stabilized phenotype (intracellular half-life >50 h). Though advantageous for following constitutive gene expression, this may obscure transient changes in gene expression. We have therefore now developed a red-shifted RLuc variant with intracellular stability comparable to that of the native enzyme.
We carried out site-specific random mutagenesis and selection as previously described 2 (Supplementary Methods). A full description of the mutagenesis screens is in Supplementary Results. Briefly, we used the destabilized variant RLuc/M185V/Q235A 3 as starting template and performed ten rounds of mutagenesis at the residue pairs Asp162/Ile163, Val185/Leu186, Asp154/Glu155, Ile159/Leu163, Glu160/Glu161, Trp156/Pro157, Ala164/Leu165, Lys136/Ile137, Phe286/Ser287 and Pro220/Arg221. Asp162 and residues in close proximity were mutated because Asp162 substitutions have previously yielded large shifts in the emission spectrum 2 , as was the case here. We also identified Asp162 mutations leading to blue-shifts ( Supplementary Fig. 1 ), but did not pursue these further. Mutations at residue 185 were probed because this residue lies at the top of the active site 4 and prior substitutions have increased quantum yield and 
Restricted ethnic diversity in human embryonic stem cell lines
To the Editor: Human pluripotent stem cells (hPSCs) have the capacity to self-renew indefinitely and to differentiate into a wide array of cell types, which make them a potential source of essentially unlimited quantities of differentiated cells for basic and clinical research. The tremendous self-renewal of hPSCs might lead one to conclude that a small number of cell lines would be sufficient to meet all needs. However, it is becoming increasingly clear that the genetic background of human cell lines can have significant effects on experimental results. Although hundreds of associations between individual alleles and specific traits or diseases are discovered each year, a full understanding of the relationships between genetic variation and cellular or organismal phenotype is still remote 1 . The HapMap project 2 , along with many other studies, has made it clear that there are large differences in the allelic frequencies for many single-nucleotide polymorphisms (SNPs) among different ethnicities. Ethnicity can serve as a proxy for genetic variation to ensure diversity in genetic backgrounds in a study population.
The availability of hPSCs from a variety of ethnic backgrounds would ensure the generalizability of results as well as increasing the likelihood that specific alleles or combinations of alleles of interest will be available for study. This is particularly important for the use of hPSCs and hPSC-derived cells for drug screening and toxicity studies. Several idiosyncratic drug effects have been attributed to specific genetic variations 3 , and the efficacy and toxicity of numerous drugs are presumed to be influenced by genetic factors. On the clinical side, hPSCs and their derivatives are potential sources for cell therapy, and recipients of cell transplants are more likely to find immunologic matches with donors who share their ethnic background. However, because most hPSC lines have been generated from de-identified material, the ethnic backgrounds of the donors are not known.
We determined the ethnic origin of 47 human embryonic stem cell (hESC) lines (including 42 standard hESC lines and 5 parthenote hESC lines), 5 hiPSC lines and 58 non-pluripotent samples (19 blood and tissue samples and 39 primary cell lines). Although this study was not intended to be comprehensive, we included hESC lines derived in a variety of geographical locations in order to sample the spectrum of ethnic diversity present in hESC lines in general (Supplementary Table 1) .
Using genome-wide SNP genotyping and Bayesian analysis of population structure (BAPS; see Supplementary Methods), we determined that the ethnic origins of the hESC lines included in this study were quite restricted (Fig. 1, Supplementary Table 1) . The large majority of hESC lines (43 of 47) were of European and East Asian ethnicity. The diversity of the hiPSC lines and nonpluripotent cells is also shown (Fig. 1, Supplementary Fig. 1 ). We note that the location of derivation of the hESC lines is not necessarily indicative of their ethnic origin. For instance, four of the five hESC lines described in one landmark publication 4 were derived in the United States (Wisconsin) but reportedly 5 came from blastocysts transported from Israel by collaborators. Our results on three of these lines indicate that they show a genetic profile similar to those of people from the region around Adygea (WA01), Tuscany (WA09) and Tuscany/Palestine (WA07), with indication of enzymatic activity 3 . We targeted residues Asp154, Glu155, Lys136 and Ser287 based on previous experiments showing increases in stability and/or enzymatic activity from mutations at these sites 2, 3 . Mutations at Pro220 were tested based on a report of increased activity with alterations at this residue 5 ; however, we were unable to find substitutions at Pro220 that increased activity or red-shift. The end result of this selection process was the variant RLuc/E155G/D162E/A164R/ L165I/M185V/Q235A/S287A, which we denote RLuc7-521.
We used purified protein to assess the bioluminescence emission spectrum, enzymatic activity and quantum yield of the new variant (Supplementary Table 1) . RLuc7-521's signal was increased 1.6-fold on a photons per second per mole basis, and its emission spectra (Fig.  1a) showed a 40-nm red-shift compared to RLuc with both coelenterazine and the substrate analog coelenterazine-v. RLuc7-521's quantum yield of 3.9 ± 0.1%, though higher than that of RLuc8.6-535 (3.1 ± 0.2%), was lower than that of RLuc (5.3 ± 0.1%), indicating that further improvements may be achievable through additional mutagenesis. We tested RLuc7-521 as a mammalian reporter gene in cell culture and observed a nearly twofold improvement in light output compared to RLuc, and an almost identical intracellular stability (Fig. 1b) .
We also tested RLuc7-521 for small-animal imaging by injecting cells transiently transfected with RLuc or RLuc7-521 into mice. Western analysis of cells before injection showed equivalent levels of luciferase protein expression between conditions ( Supplementary  Fig. 2 ). Subsequent imaging of the mice showed a 3.3-fold increase in signal output for RLuc7-521 (Fig. 1c) , a reflection of the improved light output of RLuc7-521 combined with reductions in signal attenuation by tissue for this red-shifted luciferase.
In summary, RLuc7-521 is a seven-mutation variant of RLuc that shows a green-peaked (521-nm) emission spectrum, an identical intracellular stability, and at least a twofold increase in signal, with even greater signal gains in small-animal imaging due to decreased attenuation of its red-shifted photons. This new variant represents a direct replacement of Renilla luciferase for reporter-gene applications as it retains the temporal relationship between gene activation and luciferase activity while providing greater sensitivity.
